Home Rare Cancers: Challenges and Roadmap for R&D Innovations

Drug development for Rare cancers is challenging because it is difficult to obtain relevant data from very few patients. The oncology community is increasingly facing a disproportionate fraction of the total burden of cancers, hence, requiring multi-stakeholder cooperation and collaboration to complete rare cancer trials.

Nevertheless, new insights into the biology of rare cancers have led to an explosion in knowledge and the development of targeted agents. In addition, drug development strategies and the availability of new agents for rare cancers are at risk of stalling owing to the ever-increasing complexity and costs of clinical trials. Finding solutions . . .

Access the full-content and exclusive insights by registering to futurebridge.com.

Benefits to Registered User on FutureBridge

Explore Key trends

Stay on top of your industry related trends and oppotunities.

Access to exclusive content

Get insightful information access without any restrictions.

Trending topics

Learn about fundamental challenges confronted by your industry.

Unrestricted webinar access

Gain access to all upcoming webinars and reply on-demand.

Need a thought partner?

Share your focus area or question to engage with our Analysts through the Business Objectives service.

Submit My Business Objective

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.

New Feature

Login with your mobile number. Update now.